October 2025 BioTalent funding round-up: Key trends and insights
October 2025 BioTalent funding round-up: Key trends and insights
After a slower summer period, October 2025 brought encouraging signs for biotech funding. Investment activity is picking up across multiple modalities, with strong signals in oncology, AI-driven platforms, and emerging areas like women’s health. Here’s a snapshot of the key trends shaping biotech capital flow this month.
Oncology still dominates the capital flow
Oncology remains the leading focus for investors, with ADCs, bispecifics, T-reg therapies, and next-generation immuno-oncology platforms pulling in the largest rounds globally. The data suggests no slowdown in sight, highlighting the persistent unmet need and commercial potential in this space.
AI is now mainstream
Artificial intelligence is no longer just a buzzword. From generative chemistry to robotic labs, investors are backing platforms that compress timelines and increase the probability of success. AI is rapidly becoming a foundational part of how biotech companies discover, develop, and deliver therapies more efficiently.
The US remains the investment hotspot
Across all modalities, antibodies, cell therapy, neurotech, metabolic disease, and precision delivery systems, US funding rounds consistently outpace Europe and Asia in both deal volume and average cheque size. Within Europe, the UK remains the early-stage powerhouse, France is emerging in ADCs and AI-driven platforms, and Germany/Scandinavia are landing strong rounds in cell therapy, anti-infectives, and precision biologics. The US market continues to be the place to secure the largest capital injections.
Women’s health is finally getting attention
After years of underfunding, women’s health is gaining momentum. Startups focused on endometriosis, fertility, and microbiome-driven solutions are seeing a noticeable upswing in early-stage funding. This signals a positive shift toward more inclusive healthcare innovation.
Platforms continue to win
Across geographies, the largest rounds consistently go to companies offering scalable platforms, whether in discovery, delivery, or manufacturing, rather than single-asset plays. Investors are prioritising repeatable, high-leverage technologies that reduce risk and increase potential returns.
October’s funding trends give a glimpse of where biotech investment is heading into 2026. Oncology, AI, and scalable platforms remain top priorities, but emerging areas like women’s health are beginning to diversify the investment landscape.
How BioTalent can help
Talk to the BioTalent team about what these funding trends mean for your hiring plans.
NPS Score
70+ is considered world-class
76
Get in touch
Whether you're hiring or job hunting, we're here to make the process simple. Reach out and let's talk.
All Rights Reserved 2026 BioTalent
